ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,784Medicare Part D Prescriptions Filled, Including Refills

Rank: 195 out of 2035

$565K Total Retail Price of All Prescriptions

Rank: 230 out of 2035

394 Patients Receiving at Least One Drug in Part D
78%Patients 65 Years and Older
40% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Michigan
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 394 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

18% of this provider’s 394 patients filled at least one prescription for a schedule three drug, compared to an average of 17%.

Risky Drugs to Seniors

2% of this provider’s 7,256 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$58 was the average price of a prescription from this provider, compared to $63 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Michigan
SIMVASTATIN 650 494 1 1
AMLODIPINE BESYLATE 534 469 2 6
OMEPRAZOLE 327 242 3 5
LEVOTHYROXINE SODIUM 304 220 4 4
METFORMIN HCL 300 254 5 9
HYDROCODONE-ACETAMINOPHEN 268 158 S3 6 2
LISINOPRIL 239 188 7 3
HYDROCHLOROTHIAZIDE 220 159 8 12
ZOLPIDEM TARTRATE 211 138 9 21
LOSARTAN POTASSIUM 207 173 10 15
LOSARTAN-HYDROCHLOROTHIAZIDE 194 171 11 47
ATENOLOL 165 123 12 10
SYNTHROID 164 73 13 83
METOPROLOL TARTRATE 156 104 14 8
LISINOPRIL-HYDROCHLOROTHIAZIDE 150 117 15 26
ATORVASTATIN CALCIUM 149 130 16 13
METOPROLOL SUCCINATE 142 124 17 16
CRESTOR 127 117 18 41
CLONIDINE HCL 125 91 19 61
FUROSEMIDE 124 77 20 7
AMLODIPINE BESYLATE-BENAZEPRIL 118 79 21 88
TRAMADOL HCL 105 84 22 19
AZITHROMYCIN 99 78 23 39
GABAPENTIN 98 61 24 14
ACETAMINOPHEN-CODEINE 88 54 S3 25 52
DONEPEZIL HCL 84 84 26 24
ALLOPURINOL 82 77 27 34
FLUTICASONE PROPIONATE 82 63 27 29
GLYBURIDE 80 77 R 29 74
DIOVAN 77 62 30 76
ALENDRONATE SODIUM 70 62 31 27
SERTRALINE HCL 67 58 32 23
JANUVIA 65 62 33 85
DIOVAN HCT 62 57 34 126
CYCLOBENZAPRINE HCL 60 25 R 35 64
TAMSULOSIN HCL 58 58 36 25
ADVAIR DISKUS 57 34 37 38
CLOPIDOGREL 55 55 38 30
CARVEDILOL 55 51 38 22
TRAZODONE HCL 55 32 38 50
KLOR-CON M20 54 48 41 73
RANITIDINE HCL 53 24 42 28
PRAVASTATIN SODIUM 51 37 43 17
CYMBALTA 51 35 43 59
NEXIUM 51 33 43 51
IBUPROFEN 50 32 46 43
ZETIA 50 42 46 84
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 14, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.